Payment overview · 2025
General Payments
$496.13
24 reported records · 15 companies
Healthcare provider profile · identity verified
William H Clapp, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MORGANFIELD, KY · NPI 1912973173
Verified facts
What the public records show
CMS Open Payments records show William H Clapp, M.D. received $496.13 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 37.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $185.04 | 37.3% | 6 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.55 | 9.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.92 | 6.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.88 | 6.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.17 | 4.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.04 | 4.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $22.30 | 4.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $18.31 | 3.7% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.67 | 3.6% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $17.64 | 3.6% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.14 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.03 | 3.2% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.55 | 3.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.08 | 2.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.81 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $496.13 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $155.21 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $119.43 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $105.43 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.22 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $24.17 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $23.04 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $22.30 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $18.31 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.67 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.03 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.14 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $13.81 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 205 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 90 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 66 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 74 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 99 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 58 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
90 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
58 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
99 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
205 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 958 | 164 |
| Amlodipine Besylate | Amlodipine Besylate | 682 | 149 |
| Atorvastatin Calcium | Atorvastatin Calcium | 679 | 153 |
| Omeprazole | Omeprazole | 574 | 136 |
| Gabapentin | Gabapentin | 480 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 404 | 101 |
| Furosemide | Furosemide | 398 | 98 |
| Lisinopril | Lisinopril | 345 | 77 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 321 | 74 |
| Alprazolam | Alprazolam | 307 | 47 |
| Potassium Chloride | Potassium Chloride | 307 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 301 | 68 |
| Metformin Hcl | Metformin Hcl | 291 | 75 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 269 | 40 |
| Losartan Potassium | Losartan Potassium | 254 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 247 | 52 |
| Duloxetine Hcl | Duloxetine Hcl | 237 | 49 |
| Trazodone Hcl | Trazodone Hcl | 227 | 43 |
| Tamsulosin Hcl | Tamsulosin Hcl | 222 | 51 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 53 |
| Eliquis | Apixaban | 205 | 38 |
| Prednisone | Prednisone | 200 | 93 |
| Pravastatin Sodium | Pravastatin Sodium | 188 | 41 |
| Glimepiride | Glimepiride | 187 | 39 |
| Carvedilol | Carvedilol | 181 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 170 | 53 |
| Ondansetron Hcl | Ondansetron Hcl | 169 | 51 |
| Lorazepam | Lorazepam | 168 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 164 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 157 | 46 |
| Allopurinol | Allopurinol | 149 | 32 |
| Donepezil Hcl | Donepezil Hcl | 147 | 34 |
| Ezetimibe | Ezetimibe | 146 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 30 |
| Tramadol Hcl | Tramadol Hcl | 141 | 39 |
| Diazepam | Diazepam | 140 | 22 |
| Simvastatin | Simvastatin | 140 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 138 | 51 |
| Warfarin Sodium | Warfarin Sodium | 125 | 23 |
| Famotidine | Famotidine | 124 | 22 |
| Buspirone Hcl | Buspirone Hcl | 121 | 25 |
| Sertraline Hcl | Sertraline Hcl | 120 | 30 |
| Montelukast Sodium | Montelukast Sodium | 115 | 30 |
| Amoxicillin | Amoxicillin | 110 | 84 |
| Azithromycin | Azithromycin | 108 | 82 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 23 |
| Mirtazapine | Mirtazapine | 108 | 22 |
| Promethazine Hcl | Promethazine Hcl | 107 | 31 |
| Meclizine Hcl | Meclizine Hcl | 104 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 100 | 16 |
| Ozempic | Semaglutide | 99 | 17 |
| Pregabalin | Pregabalin | 98 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 30 |
| Spironolactone | Spironolactone | 97 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 92 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 21 |
| Farxiga | Dapagliflozin Propanediol | 90 | 23 |
| Amitriptyline Hcl | Amitriptyline Hcl | 89 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 16 |
| Cephalexin | Cephalexin | 81 | 58 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 80 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 20 |
| Mounjaro | Tirzepatide | 74 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 73 | 22 |
| Clonidine Hcl | Clonidine Hcl | 71 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 71 | 48 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 69 | 41 |
| Temazepam | Temazepam | 69 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 68 | 16 |
| Synthroid | Levothyroxine Sodium | 67 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 29 |
| Xarelto | Rivaroxaban | 67 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 66 | 44 |
| Jardiance | Empagliflozin | 66 | 15 |
| Cefuroxime | Cefuroxime Axetil | 64 | 41 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 15 |
| Finasteride | Finasteride | 64 | 14 |
| Baclofen | Baclofen | 62 | 12 |
| Levetiracetam | Levetiracetam | 62 | suppressed |
| Cilostazol | Cilostazol | 61 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 14 |
| Fluconazole | Fluconazole | 59 | 33 |
| Nitroglycerin | Nitroglycerin | 58 | 43 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 58 | 13 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 57 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 54 | 11 |
| Mupirocin | Mupirocin | 51 | 31 |
| Ventolin Hfa | Albuterol Sulfate | 51 | 18 |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Celecoxib | Celecoxib | 49 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 15 |
| Topiramate | Topiramate | 48 | suppressed |
| Methocarbamol | Methocarbamol | 47 | 16 |
| Clonazepam | Clonazepam | 44 | 11 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Estradiol | Estradiol | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 41 | suppressed |
| Memantine Hcl | Memantine Hcl | 40 | suppressed |
| Colchicine | Colchicine | 39 | 15 |
| Diltiazem Hcl | Diltiazem Hcl | 38 | suppressed |
| Entresto | Sacubitril/Valsartan | 38 | suppressed |
| Naproxen | Naproxen | 38 | 11 |
| Repatha Sureclick | Evolocumab | 37 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Meloxicam | Meloxicam | 35 | suppressed |
| Methotrexate | Methotrexate Sodium | 35 | suppressed |
| Novolog Flexpen | Insulin Aspart | 34 | 11 |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Nystatin | Nystatin | 33 | 19 |
| Metronidazole | Metronidazole | 32 | 23 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 32 | suppressed |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Dutasteride | Dutasteride | 30 | suppressed |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | 14 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Minoxidil | Minoxidil | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Oxycontin | Oxycodone Hcl | 25 | suppressed |
| Risperidone | Risperidone | 25 | suppressed |
| Loperamide | Loperamide Hcl | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 12 |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 21 | suppressed |
| Pentoxifylline | Pentoxifylline | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trospium Chloride | Trospium Chloride | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Glyburide | Glyburide | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 14 | suppressed |
| Aliskiren | Aliskiren Hemifumarate | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Ingrezza | Valbenazine Tosylate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ramipril | Ramipril | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Dexilant | Dexlansoprazole | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Multaq | Dronedarone Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $496.13 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, ELIQUIS, EVENITY, FANAPT, FARXIGA, HETLIOZ, JARDIANCE, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, Omnipod, Ozempic, QULIPTA, REPATHA, REXULTI, TRELEGY ELLIPTA, VOQUEZNA, VYEPTI, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error